Sunday, October 18, 2026

@partners_road 33h ago 6 clicks

RiverRoadPartners on X

@Qweezy80k Did you read what I posted? To repeat: there are limited Korean ETF shorts to cover. There are very limited US memory ($MU, $SNDK, $WDC) shorts. Leveraged memory ETF (long) positioning is quite high. All of that is 100% in contradiction to your post.

@BarbarianCap 33h ago 7 clicks

Barbarian Capital on X

3/n $SBUX CEO on the @CapitalGroup pod on the turnaround efforts + more Also covers his time at $YUM $CMG $PG https://t.co/PI6oUxsXLE

@BarbarianCap 33h ago 9 clicks

Barbarian Capital on X

2/n $NU founder/CEO @velez_david with @patrick_oshag Crash course on banking economics, how tech impacts banking, cash-to-digital global opportunity, management/leadership, AI implementation https://t.co/osqyHHD0kY

@calvinblissett 33h ago

Calvin Blissett on X

@rebv808 I believe I covered the first question, so I mean it when I say that’s a great question. You mean on the latter % of customers that $CCLD already has as RCM that don’t use EHR right?

@calvinblissett 35h ago 8 clicks

Calvin Blissett on X

$CCLD questions I have so far for Stephen Synder (CEO) interview if I am missing anything please let me know Charlie Munger famously talked about the importance of distinguishing between technological improvements where the economic benefits “stick to our ribs as owners” and those where “all of the advantages from great improvements are going to flow through to the customers.” (Stripe Press) I think it’s fair to say AI will lower costs overall for the RCM industry for those able to take advantage of it. McKinsey estimates that AI enablement of the revenue cycle could reduce cost to collect by 30% to 60%. (McKinsey & Company) We are already beginning to see this play out: roughly 20% to 40% of organizations report broad or enterprise-wide use of AI-enabled tools across different parts of the revenue cycle, while 70% to 90% of decision-makers expect to increase spending on AI-enabled RCM capabilities over the next three years. (Oliver Wyman) How is this playing out currently, and how do you see it progressing? More specifically, where do you think the economic benefits of AI ultimately accrue? Will AI make the strong stronger and the weak weaker—allowing scaled, technologically capable RCM providers to lower their costs faster and potentially furthering industry consolidation? Or, as AI tools become increasingly commoditized and accessible, could they instead level the playing field and erode some of CareCloud’s existing competitive cost advantage? A bit similar to the last question: Could AI change the dynamic of struggling companies not being able to upgrade products and or win clients. Allowing them to improve and compete hence lowering acquisition opportunities? How much growth aside from obviously inorganic acquisitions is existing customers expanding versus new clinics signing up? Do you think about size when acquiring or is it purely a factor of opportunity and fit. It would seem intuitive smaller acquisitions are easier and cheaper. Is there a pace or target you have in mind regarding acquisitions One shareholder asked for more metrics/metrics with news. Just granularity, Shareholder assumes it will be on earnings call but affects of data breach and portion if any that isn’t covered by insurance. What you’re seeing and anticipate seeing in terms of loss of current customers and momentum in future sales. A majority of the employees are in Pakistan which is currently going through a turbulent time and is basically a junta. Do you think there's any need to de-risk it? I believe the ROI from acquisition is at the midpoint of purchase multiple (.6-1x) and target contribution margin (25-30%) on a full year time frame after 9 months to get there to be About 34%. If your stock had the same FCF yield how would you weight buybacks vs acquisitions. Given the same assumed 34% full year after achieving targets on acquisition In Q2 2026, Hadi said: “OurAI and acquisition strategies have become a single, unified growth engine.” Does that mean that AI strategy/product development has similar economics or is it table stakes and has to be invested in merely to keep up?

@BarbarianCap 35h ago

Barbarian Capital on X

Accenture looks to sell Chinese operations for up to $1.5 bn $ACN https://t.co/0LrYwpiFkl

@BarbarianCap 35h ago 3 clicks

Barbarian Capital on X

Evercore appoints co-presidents for the first time in leadership reshuffle $EVR https://t.co/XTqr3gW9jX

@ACapitalLP 36h ago

A Capital on X

Fair points, but I think you’re conflating capital markets access with the economics of the underlying contracts. A pulled equity offering doesn’t mean secured project financing has disappeared. And more importantly, $CRWV and $CIFR have fundamentally different business models, funding requirements and residual asset values. That’s precisely my point.